For AbbVie Inc., Humira (adalimumab) is always the elephant in the room – and it has been since the firm's spinout from Abbott Laboratories Inc. in 2013. As the company pumps up investor expectations for late-stage candidates to expand its immunology portfolio and leverage Humira, a pair of executives reviewed the strategic choices AbbVie has made since its inception.
Chief Financial Officer Bill Chase and Scott Brun, divisional VP of infectious diseases and immunology development, detailed this strategy during...








